Investor Relations

OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015 more »

FDA Accepts OPKO's New Drug Application for Rayaldee™ more »

OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults more »

OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources more »

Investor FAQs